Perspectives on Biologically Active Camptothecin Derivatives

Medicinal Research Reviews

Volumn 35, Issue 4, 2015, Pages 753-789

  Liu, Ying Qian ^a,b   Li, Wen Qun ^a   Morris Natschke, Susan L ^c   Qian, Keduo ^c   Yang, Liu ^d   Zhu, Gao Xiang ^a   Wu, Xiao Bing ^a   Chen, An Liang ^b   Zhang, Shao Yong ^b   Nan, Xiang ^a   Lee, Kuo Hsiung ^c,e  

^a LANZHOU UNIVERSITY   (China)

^b ZHEJIANG A F UNIVERSITY   (China)

^c University of North Carolina   (United States)

^d LANZHOU JIAOTONG UNIVERSITY   (China)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Biological activities; Camptothecins; DNA topoisomerase I; Structure activity relationship

Indexed keywords

10 HYDROXYCAMPTOTHECIN; 9 AMINOCAMPTOTHECIN; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIPSORIASIS AGENT; ANTIVIRUS AGENT; CAMPTOTHECIN DERIVATIVE; FIRTECAN; IRINOTECAN; PESTICIDE; TOPOTECAN; ANTIINFECTIVE AGENT; CAMPTOTHECIN;

ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG ACTIVITY; DRUG CYTOTOXICITY; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); CHEMISTRY;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; HUMANS;

EID: 84930581497     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21342     Document Type: Article

References (152)

1. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966;88:3888-3890.
2. Gottlieb JA, Guarino AM, Call JB, Oliverio VT, Block JB. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 1970;54:461-479.
3. Muggia FM, Creaven PJ, Jansen HH, Cohen MN, Selawry DS. Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother Rep 1972;56:515-521.
4. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972;56:95-101.
5. Potmesil M, Kohn KW, Eds. DNA Topoisomerases in Cancer.New York:Oxford University; 1991.
6. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878.
7. Potmesil M, Pinedo H, Eds. Camptothecins: New Anticancer Agents. Boca Raton:CRC; 1995.
8. Onishi H, Machida Y. Macromolecular and nanotechnological modification of camptothecin and its analogs to improve the efficacy. Curr Drug Discover Technol 2005;2:169-183.
9. Houghton PJ, Cheshire PJ, Myers L, Stewart CF, Synold TW, Houghton JA. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother Pharmacol 1992;31:229-232.
10. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-5948.
11. Ahn SK, Choi NS, Jeong BS, Kim KK, Journ DJ, Kim JK. Practical synthesis of (S)-7-(2-isopropylamino)ethylcamptothecin hydrochloride, potent topoisomerase I inhibitor. J Heterocycl Chem 2000;37:1141-1144.
12. Wani MC, Nicholas AW, Wall ME. Plant antitumor agents 23. Synthesis and antileukemic activity of camptothecin analogs. J Med Chem 1986;29:2358-2363.
13. van Hattum AH, Pinedo HM, Schluper HMM, Erkelens CAM, Tohgo A, Boven E. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer. Biochem Pharm 2002;64:1267-1277.
14. Royce ME, Rowinsky EK, Hoff PM, Coyle J, DeJager R, Pazdur R. A phase II study of intravenous exatecan mesylate (DX- 8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum. Invest New Drugs 2004;22:53-61.
15. Stevenson JP, DeMaria D, Sludden J, Kaye SB, Paz-Ares L, Grochow LB. Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion. Ann Oncol 1999;10:339-344.
16. Giles FJ, Tallman MS, Guillermo GM, Cortes JE, Thomas DA, Wierda WG. Phase I and pharmacokinetic study of a low clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase I inhibitor, in patients with advanced leukemia. Cancer 2004;100:1449-1458.
17. Dong P, Zuo C, Chen ZL, Gao Y, inventors: Jiangsu Chia0tai Tianqing Pharmaceutical Co. Ltd, assignee. Pharmaceutical composition of camptothecin derivative and preparation method thereof. China Patent CN102764260.A. 2012. 11.7, 2012.
18. Yu Y, Zhan Y, Chen Z, Zhang, Y, Zhong D. Development and validation of a sensitive LC-MS/MS method for simultaneous quantification of sinotecan and its active metabolite in human blood. J Chromatogr B 2014;951-952:62-68.
19. Koshkina NV, Kleinerman ES, Waidrep C, Jia SF, Worth LL, Gilbert BE. 9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastasis in mice. Clin Cancer Res 2000;6:2876-2880.
20. Verschraegen CF, Gilbert BE, Huaringa AJ, Newman R, Harris N, Leyva FJ. Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann N Y Acad Sci 2000;922:352-354.
21. Takimoto CH, Thomas R. The clinical development of 9-aminocamptothecin. Ann N Y Acad Sci 2000;922:224-236.
22. Pratesi G, Beretta GL, Zunino F. Gimatecan, a novel camptothecin with a promising preclinical profile. Anticancer Drugs 2004;15:545-552.
23. Haridas, K, Hausheer, FH. Preparation of highly lipophilic camptothecin derivatives. U.S. patent 6057303, 2000.
24. Bom D, Curran DP, Zhang J, Zimmer SG, Bevins R, Kruszewski S. The highly lipophilic DNA topoisomerase I inhibitor DB-67 displays elevated lactone levels in human blood and potent anticancer activity. J Control Release 2001;74:325-333.
25. Demarquay D, Huchet M, Coulomb H. The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs 2001;12:9-19.
26. Lavergne O, Lesueur-Ginot L, Pla Rodas F, Kasprzyk PG, Pommier J, Demarquay D, Prévost G, Ulibarri G, Rolland A, Schiano-Liberatore AM, Harnett J, Pons D, Camara J, Bigg DC. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogs. J Med Chem 1998;41:5410-5419.
27. Lerchen HG, Baumgarten J, von dem Bruch K, Lehmann TE, Sperzel M, Kempka G, Fiebig HH. Design and optimization of 20-O-linked camptothecin glycoconjugates as anticancer agents. J Med Chem 2001;44:4186-4195.
28. Singer JW, Bhatt R, Tulinsky J, Buhler KR, Heasley E, Klein P, de Vries P. Water-soluble poly-(L-glutamic acid)-Gly-camptothecin conjugates enhance camptothecin stability and efficacy in vivo. J Control Release 2001;74:243-247
29. Greenwald RB, Pendri A, Conover C, Gilbert C, Yang R, Xia J. Drug delivery systems. 2. Camptothecin 20-O-polyethylene glycol ester transport forms. J Med Chem 1996;39:1938-1940.
30. Slichenmyer, W. J, Rowinsky EK, Donehower RC, Kaufmann SH. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993;85:271-290.
31. Schultz AG. Camptothecin. Chem Rev 1973;73:385-405.
32. Wall ME, Wani MC. Camptothecin and taxol: From discovery to clinic. J Ethnopharmacol 1996;51:239-254.
33. Leary OJ, Muggia FM. Camptothecins: A review of their development and schedules of administration. Eur J Cancer 1998;34:1500-1508.
34. Oberlies NH, Kroll DJ. Camptothecin and taxol: Historic achievements in natural products research. J Nat Prod 2004;67:129-135.
35. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-2242.
36. Lorence A, Nessler CL. Camptothecin, over four decades of surprising findings. Phytochem 2004;65:2735-2749
37. Zunino F, Dallavalle S, Laccabue D, Beretta G, Merlinib L, Pratesi G. Current status and perspectives in the development of camptothecins. Curr Pharm Design 2002;8:2505-2520.
38. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: Current perspectives. Bioorg Med Chem 2004;12:1585-1604.
39. Driver RW, Yang LX. Synthesis and pharmacology of new camptothecin drugs. Mini Rev Med Chem 2005;5:425-439.
40. Lerchen HG. Milestones in camptothecin research. Drugs Future 2002;27:869-878.
41. Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Camptothecin and its analogues: A review on their chemotherapeutic potential. Nat Prod Res 2005;19:393-412.
42. Pommier Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
43. de Cesare M, Beretta GL, Tinelli S, Benedetti V, Pratesi G, Penco S, Dallavalle S, Merlini L, Pisano C, Carminati P, Zunino F. Preclinical efficacy of ST1976, a novel camptothecin analog of the 7-oxyiminomethyl series. Biochem Pharmacol 2007;73:656-664.
44. Dallavalle S, Merlini L, Morini G, Musso L, Penco S, Beretta GL, Tinelli S, Zunino F. Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin. Eur J Med Chem 2004;39:507-513.
45. Dallavalle S, Rocchetta DG, Musso L, Merlini L, Morini G, Penco S, Tinelli S, Beretta GL, Zunino F. Synthesis and cytotoxic activity of new 9-substituted camptothecins. Bioorg Med Chem Lett 2008;18:2781-2787.
46. Li MZ, Jin W, Jiang C, Zheng C, Tang WD, You TP, Lou LG. 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation. Bioorg Med Chem Lett 2009;19:4107-4109.
47. Liu YQ, Dai W, Wang CY, Morris-Natschke SL, Zhou XW, Yang L, Yang XM, Li WQ, Lee KH. Design and one-pot synthesis of new 7-acyl camptothecin derivatives as potent cytotoxic agents. Bioorg Med Chem Lett 2012;22:7659-7661.
48. Xiao F, Xue YD, Luo Y, Zhang B, Lu W, Yang B. Synthesis and cytotoxic activity of 7-alkynyl camptothecin derivatives. Chin Chem Lett 2009;20:566-568.
49. Li QY, Zu YG, Shi RZ, Yao LP, Fu YJ, Yang ZW, Li L. Synthesis and antitumor activity of novel 10-substituted camptothecin analogues. Bioorg Med Chem 2006;14:7175-7182.
50. Jiao Y, Liu HC, Geng MY, Duan WH. Synthesis and antitumor activity of 10-arylcamptothecin derivatives. Bioorg Med Chem Lett 2011;21:2071-2074.
51. Gao HY, Zhang XW, Chen Y, Shen HW, Sun J, Huang M, Ding J, Li C, Lu W. Synthesis and antitumor activity of 7-ethyl-9-alkyl derivatives of camptothecin. Bioorg Med Chem Lett 2005;15:2003-2006.
52. Wang S, Li YY, Liu YH, Lu AJ, You QD. Novel hexacyclic camptothecin derivatives. Part 1: Synthesis and cytotoxicity of camptothecins with an A-ring fused 1, 3-oxazine ring. Bioorg Med Chem Lett 2008;18:4095-4097.
53. Niizuma S, Tsukazaki M, Suda H, Murata T, Ohwada J, Ozawa S. Synthesis of new camptothecin analogs with improved antitumor activities. Bioorg Med Chem Lett 2009;19:2018-2021.
54. Leu YL, Chen CS, Wu YJ, Chern JW. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J Med Chem 2008;51:1740-1746.
55. Comins DL. Camptothecin intermediate and method of making camptothecin intermediates US patent 5459269, 1995.
56. Sawada S, Matsuoka S, Nokata K, Nagata H, Furata T, Yokokura T, Miyasaka T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: A-ring modified and 7, 10-disubstituted camptothecins. Chem Pharm Bull 1991;12:3183-3188.
57. Cao ZS. Preparation of 14-nitrocamptothecin derivatives by reactions of camptothecin with nitronium tetrafluoroborate in acidic solvents. J Chem Soc Perkin Trans I 1996;1:2629-2631.
58. Cheng KJ, Rahier NJ, Eisenhauer BM, Gao R, Thomas SJ, Hecht SM. 14-Azacamptothecin: A potent water-soluble topoisomerase I poison. J Am Chem Soc 2005;127:838-839.
59. Samorì C, Guerrini A, Varchi G, Zunino F, Beretta GL, Femoni C, Bombardelli E, Fontana G, Battaglia A. Thiocamptothecin. J Med Chem 2008;51:3040-3044.
60. Duan JX, Cai X, Meng F, Sun JD, Liu Q, Jung D, Jiao H, Matteucci J, Jung B, Bhupathi D, Ahluwalia D, Huang H, Hart CP, Matteucci M. 14-Aminocamptothecins: Their synthesis, preclinical activity, and potential use for cancer treatment. J Med Chem 2011;54:1715-1723.
61. Subrahmanyam D, Venkateswarlu A, Rao KV, Sastrya TVRS, Vandana G, Kumar SA. Novel C-ring analogues of 20(S)-camptothecin. Part-2: Synthesis and in vitro cytotoxicity of 5-C-substituted 20(S)-camptothecin analogues. Bioorg Med Chem Lett 1999;9:1633-1638.
62. Subrahmanyam D, Sarma VM, Venkateswarlu A, Sastry TV, Srinivas AS, Krishna CV, Deevi DS, Kumar SA, Babu MJ, Damodaran NK. Novel C-ring analogues of 20(S)-camptothecin. Part 3: Synthesis and their in vitro cytotoxicity of A-, B- and C-ring analogues. Bioorg Med Chem Lett 2000;10:369-371.
63. Subrahmanyam D, Sarma VM, Venkateswarlu A, Sastry TVRS, Kulakarni AP, Rao DS, Reddy KVSRK. In vitro cytotoxicity of 5-aminosubstituted 20(S)-camptothecins. Part 1. Bioorg Med Chem 1999;7:2013-2020.
64. Chatterjee A, Digumarti R, Mamidi RNVS, Katneni K, Upreti VV, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, Subramaniam S, Srinivas NR. Safety, tolerability, pharmacokinetics, and pharmacodynamics of an orally active novel camptothecin analog, DRF-1042, in refractory cancer patients in a phase I dose escalation study. J Clin Pharmacol 2004;44:723-736.
65. Samori C, Guerrini A, Varchi G, Fontana G, Bombardelli E, Tinelli S. Semisynthesis, biological activity, and molecular modeling studies of C-ring-modified camptothecins. J Med Chem 2009;52:1029-1039.
66. Deshmukh M, Chao PY, Kutscher HL, Gao DY, Sinko PJ. A series of α-amino acid ester prodrugs of camptothecin: In vitro hydrolysis and A-549 human lung carcinoma cell cytotoxicity. J Med Chem 2010;53:1038-1047.
67. Wang CY, Pan XD, Liu HY, Fu ZD, Wei XY, Yang LX. Synthesis and antitumor activity of 20-O-linked nitrogen-based camptothecin ester derivatives. Bioorg Med Chem 2004;12:3657-3662.
68. Li QY, Lv HY, Zu YG, Qu ZH, Yao LP, Su L, Liu C, Wang LM. Synthesis and antitumor activity of novel 20-camptothecin analogues. Bioorg Med Chem Lett 2009;19:513-515.
69. Liu YQ, Tian X, Yang L, Zhan ZC. First synthesis of novel spin-labeled derivatives of camptothecin as potential antineoplastic agents. Eur J Med Chem 2008;43:2610-2614.
70. Rahier NJ, Eisenhauer BM, Gao R, Thomas SJ, Hecht SM. On the role of E-ring oxygen atoms in the binding of camptothecin to the topoisomerase I-DNA covalent binary complex. Bioorg Med Chem 2005;13:1381-1386.
71. Lesueur-Ginot L, Demarquay D, Kiss R. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res 1999;59:2939-2943.
72. Lavergne O, Demarquay D, Bailly C. Preparation and in vitro activity of enantiomerically pure, fluorinated homocamptothecins as potent topoisomerase I poisons. J Med Chem 2000;43:2285-2289.
73. Larsen A, Gilbert C, Chyzak G. Unusual potency of BN80915, a novel fluorinated E-ring modified camptothecin, towards human colon carcinoma cells. Cancer Res 2001;61:2961-2967.
74. Guo W, Miao ZY, Sheng CQ, Yao JZ, Feng H. Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I. Eur J Med Chem 2010;45:2223-2228.
75. Zhu LJ, Zhang XH, Lei N. Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors. Chem Biodivers 2012;9:1084-1094.
76. Miao ZY, Zhang J, You L, Wang J, Sheng CQ, Yao JZ. Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities. Bioorg Med Chem 2010;18:3140-3146.
77. Zhu LJ, Zhuang CL, Lei N, Guo ZZ, Sheng CQ, Dong GQ. Synthesis and preliminary bioevaluation of novel E-ring modified acetal analog of camptothecin as cytotoxic agents. Eur J Med Chem 2012;56:1-9.
78. Luo Y, Yu SB, Tong LJ, Huang QQ, Lu W, Chen Y. Synthesis and biological evaluation of new homocamptothecin analogs. Eur J Med Chem 2012;54:281-286.
79. Liu WF, Zhu LJ, Guo W, Zhuang CL, Zhang YQ. Synthesis and biological evaluation of novel 7-acyl homocamptothecins as topoisomerase I inhibitors. Eur J Med Chem 2011;46:2408-2414.
80. Li MZ, Tang WD, Zeng FX, Lou LG, You TP. Semi-synthesis and biological activity of β-lactones analogs of camptothecin. Bioorg Med Chem Lett 2008;18:6441-6443.
81. Miao ZY, Zhu LJ, Dong GQ, Zhuang CL, Wu YL, Wang SZ, Guo ZZ, Liu Y, Wu SC, Zhu SP, Fang K, Yao JZ, Li J, Sheng CQ, Zhang WN. A new strategy to improve the metabolic stability of lactone: discovery of (20S, 21S)-21-fluorocamptothecins as novel, hydrolytically stable topoisomerase I inhibitors. J Med Chem 2013;56:7902-7910.
82. Wang MJ, Liu YQ, Chang LC, Wang CY, Zhao YL, Zhao XB, Qian KD, Nan X, Yang L, Yang XM, Hung HY, Yang JS, Kuo DH, Goto M, Morris-Natschke SL, Pan SL, Teng CM, Kuo SC, Wu TS, Wu YC, Lee KH. Design, synthesis, mechanisms of action, and toxicity of novel 20(S)-sulfonylamidine derivatives of camptothecin as potent antitumor agents. J Med Chem 2014;57:6008-6018.
83. Hizi A, Gazit A, Buthmann D, Yaniv A. DNA processing activities associated with the purified α, β2, αβ2 molecular forms of avian sarcoma virus RNA-dependent DNA polymerase. J Virol 1982;141:974-981.
84. Weiss R, Teich N, Varmus H, Coffin J. In: Molecular Biology of Tumor Viruses: RNA Tumor Viruses, 2nd ed. New York: Cold Spring Harbor; 1985.
85. Priel E, Aflalo E, Chechelnitsky G, Benharroch D, Aboud M, Segal S. Inhibition of retrovirus-induced disease in mice by camptothecin. J Virol 1993;167:3624-3629.
86. Priel E, Showalter SD, Roberts M, Oroszlan S, Segar S, Aboud M, Blair DG. Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. EMBO J 1990;12:4167-4172.
87. Pantazis P. Camptothecin: A promising antiretroviral drug. J Biomed Sci 1996;3:14-19.
88. Horwitz SB, Chang CK, Grollman AP. Studies on camptothecin: Effects on nucleic acid and protein synthesis. Mol Pharmacol 1971;7:632-644.
89. Horwitz SB, Chang CK, Grollman AP. Antiviral action of camptothecin. Antimicrob Agents Chemother 1972;2:395-401.
90. Priel E, Showalter SD, Blair DG. Inhibition of human immunodeficiency virus (HIV-1) replication by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses 1991;7:65-72.
91. Priel E, Showalter SD, Roberts M, Oroszlan S, Blair DG. The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells. J Virol 1991;65:4137-4141.
92. Wong-Staal F. Human immunodeficiency viruses and their replication. In: Fields BN, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B, eds. Virology, Vol 2. New York: Raven Press; 1990. p 1529-1543.
93. Li CJ, Zhang LJ, Dezube B J, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat directed gene expression and virus replication. Proc Natl Acad Sci USA 1993;90:1839-1842.
94. Royal W, Dupont B, McGuire D, Chang L, Goodkin K, Ernst T, Post MJ, Fish D, Pailloux G, Poncelet H, Concha M, Apuzzo L, Singer E. Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy. J Neurovirol 2003;9:411-419.
95. Sadaie MR, Doniger J, Hung CL, Pantazis P. 9-Nitrocamptothecin selectively inhibits human immunodeficiency virus type 1 replication in freshly infected parental but not 9-nitrocamptothecin-resistant U937 monocytoid cells. AIDS Res Hum Retrovirus 1999;15:239-245.
96. Li YY, Chen SW, Yang LM, Wang RR, Pang W, Zheng YT. The anti-HIV actions of 7- and 10-substituted camptothecins. Molecules 2009;15:138-148.
97. Pantazis P. Camptothecin: A promising antiretroviral drug. J Biomed Sci 1996;3:14-19.
98. Pantazis P, Han ZY, Chatterjee D, Wyche J. Camptothecin: A promising antiretroviral drug. J Biomed Sci 1999;6:1-7.
99. Yamada Y, Yamamoto N, Maeno K, Nishiyama Y. Role of DNA topoisomerase I in the replication of herpes simplex virus type 2. Arch Virol 1990;110:121-127.
100. Das B, Madhusudhan P, Kashinatham A. Two efficient methods for the conversion of camptothecin to mappicine ketone, an antiviral lead compound. Tetrahedron Lett 1998;39:431-432.
101. de Clercq E. Antiviral drugs: Current state of the art. J Clin Virol 2001;22:73-89.
102. Pendrak I, Wittrock R, Kingsbury WD. Synthesis and anti-HSV activity of methylenedioxy mappicine ketone analogs. J Org Chem 1995;60:2912-2915.
103. Liu YQ, Liu ZL, Tian X, Yang L. Anti-HSV activity of camptothecin analogues. Nat Prod Res 2010;24:509-514.
104. DeMilo AB, Borkovec AB. Camptothecin, a potent chemosterilant against the house fly. J Econ Entomol 1974;67:457-458.
105. Borkovec AB. Control and management of insect populations by chemosterilants. Environ Health Perspect 1976;14:103-107.
106. Hu Q, Han BY, Ma JY, Tang D, Yang J. Field efficiency trials on Empoasca vitis Gothe with extractive from the leaf of Camptotheca acuminate. China Tea 2009;31:32-33.
107. Tong SM, Wang PW, Sun YZ, Zhang LQ, Ma JY, Sheng XQ. Insecticidal effect of camptothecin against Nilaparvata lugens, Brevicoryne brassicae and Chilo suppressalis Walker. Acta Agri Zhejiangensis 2009;21:288-292.
108. de L, Jiang HY, Zhang YN, Zhang L, He WZ. Insecticidal activity of camptothecin derivatives. Plant protection science and technology innovation and pest prevention and control specialization. China Plant Protection Association 2011 Annual Conference Proceedings, 2011.
109. Ma JY, Tong SM, Wang PW, Liao WL, Liu HB, Zhang LQ. Insecticidal activity of camptothecin against Nilaparvata lugens, Brevicoryne brassicae, and Chilo suppressalis. J Econ Entomol 2010;103:492-496.
110. Sun SF, Cheng ZS, Fan J, Cheng XH, Pang Y. The utility of camptothecin as a synergist of Bacillus thuringiensis var. kurstaki and nucleopolyhedroviruses against Trichoplusia ni and Spodoptera exigua. J Econ Entomol 2012;105:1164-1170.
111. Wang WX, Zhong GH, Hu MY, Huang JF, Ge CC. Induced apoptosis of camptothecin in Spodoptera frugiperda Sf9 cells. Acta Entomol Sinica 2011;54:894-901.
112. Zhang L, Zhang YN, He WZ, Ma DJ, Jiang HY. Effects of camptothecin and hydroxycamptothecin on insect cell lines Sf21 and IOZCAS-Spex-II. Pest Manag Sci 2012;68:652-657.
113. Zhang L, Ma DJ, Zhang YN, He WZ, Yang JJ, Li CR, Jiang HY. Characterization of DNA topoisomerase-1 in Spodoptera exigua for toxicity evaluation of camptothecin and hydroxycamptothecin. PLoS One 2013;8:e56458.
114. Liu YQ, Yang L, Zhao YL, Li HY. Synthesis of novel derivatives of camptothecin as potential insecticides. Pest Biochem Physiol 2010;98:219-223.
115. Liu YQ, Dai W, Tian J. Synthesis and insecticidal activities of novel spin-labeled derivatives of camptothecin. Heteroatom Chem 2011;22:687-691.
116. Zhang SY. Structure-insecticide activity relationship on camptothecin derivants. Master's dissertation, Zhejiang A&F University, 2011.
117. Zhang SY, Chen AL, Zhang LQ. Nematocidal activity against pine wood nematode (Bursaphelenchus xylophilus) of 7-C-substituted 20-(S)-camptothecins. Chin J Pestic Sci 2011;13:127-132.
118. Li WQ, Liu YQ, Zhao YL, Zhou XW, Yang L, Feng G, Kou L. Antifeedant activity of camptothecin and its semisynthetic derivatives against Spodoptera litura (Fabricius) (Lepidoptera:Noctuidae) larvae. Curr Bioact Compd 2012;8:291-295.
119. Li SY, Nacogdoches TX. Utilizing camptotheca products for termite control. US 2002/0018762 Al.
120. Deterding A, Dungey FA, Thompson KA, Steverding D. Antitrypanosomal activities of DNA topoisomerase inhibitors. Acta Trop 2005;93:311-316.
121. Bodley AL, Cumming JN, Shapiro TA. Effect of camptothecin, a topoisomerase I inhibitor on Plasmodium falciparum. Biochem Pharmacol 1998;55:709-711.
122. Bodley AL, Shapiro TA. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc Natl Acad Sci USA 1995;92:3726-3730.
123. Bodley AL, Wani MC, Wall ME, Shapiro TA. Antitrypanosomal activity of camptothecin analogs. structure-activity correlations. Biochem Pharmacol 1995;50:937-942.
124. Werbovetz KA, Bhattacharjee AK, Brendle JJ, Scovill JP. Analysis of stereoelectronic properties of camptothecin analogues in relation to biological activity. Bioorg Med Chem 2000;8:1741-1747.
125. Proulx ME, Desormeaux A, Marquis JF, Olivier M, Bergeron MG. Treatment of visceral leishmaniasis with sterically stabilized liposomes containing camptothecin. Antimicrob Agents Chemother 2001;45:2623-2627.
126. Chiao C, Li H. Effect of topical use of camptothecine-dimethyl sulfoxide solution in psoriasis. Chin Med J (Engl) 1975;1:355-360.
127. Psoriasis Research Group. Department of Dermatology, 1st Hospital, Beijing Medical College. Chemotherapy for psoriasis. Chin J Dermatol 1980;13:61-63.
128. Lin XR, Huang T, Yang CM. The effect of camptothecine in treating psoriasis. Natl Med J China 1987;67:4-6.
129. Lin XR, Huang T. Topical camptothecine in treatment of psoriasis. Int J Dermatol 1988;27:475-476.
130. Wang XB, Luo L, Zeng J. Clinical observation of 10-hydroxycamptothecin on treatment of psoriasis. J Dermatol Venereol 2001;1:30-31.
131. Lin XR, Wilkinson DI, Farber EM. Camptothecin induces differentiation, tissue transglutaminase and apoptosis in cultured keratinocytes. Exp Dermatol 1998;7:179-183.
132. Lin XR, Wilkinson DI, Huang T, Farber EM. Experimental studies on topoisomerase inhibitor camptothecin as an antipsoriatic agent. Chin Med J (Engl) 1999;112:504-508.
133. Lin JR, Liu XM, Bao YM, Hou SC, An LJ, Lin XR. Effects of isocamptothecin, a novel camptothecin analogue, on proliferation, apoptosis and telomerase activity in HaCaT cells. Exp Dermatol 2008;17:530-536.
134. Liu X, Lin J, Bao Y, Lin X, An L. Camptothecin-mediated apoptosis and antiproliferation effect is accompanied by down-regulation of telomerase activity in HaCaT cells. J Dermatol Sci 2006;42:262-264.
135. del Poeta M, Chen SF, von Hoff D, Dykstra CC, Wani MC, Manikumar G, Heitman J, Wall ME, Perfect JR. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob Agents Chemother 1999;43:2862-2868.
136. Li SY, Zhang ZZ, Cain AG, Wang B, Long M, Taylor J. Antifungal activity of camptothecin, trifolin, and hyperoside isolated from Camptotheca acuminata. J Agric Food Chem 2005;53:32-37.
137. Zhang LQ, Sun YZ, Wang PW, Tong SM, Ma LJ. Antifungal activity of camptothecin on Rhizoctonia solani, Sphaerotheca fuliginea and Pseudoperonospora cubensis. J Zhejiang Forestry College 2008;25:681-684.
138. Alaghaz ANMA, El-Sayad BA, Salwa AHA. Synthesis, spectroscopic, and antimicrobial activity studies of novel 10-substituted camptothecin phosphorothioate analogs. Phosphorus Sulfur Silicon Relat Elem 2012;187:799-807.
139. Rapisarda A, Urachimeg B, Scudiero DA, Selby M, Sausville EA, Shoemaker RH, Melillo G. Identification of small molecule inhibitors of hypoxia-inducible factor I transcriptional activation pathway. Cancer Res 2002;62:4316-4324.
140. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004;64:1475-1482.
141. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Hewitt SM, Shoemaker RH, Melillo G. Schedule-dependent inhibition of hypoxia-inducible factor-1 protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004;64:6845-6848.
142. Rapisarda A, Shoemaker RH, Melillo G. Targeting topoisomerase I to inhibit hypoxia inducible factor 1. Cell Cycle 2004;3:172-175.
143. Torregrossa J, Bubley GJ, Jones GB. Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1a. Bioorg Med Chem Lett 2006;16:6082-6085.
144. Klausmeyer P, McCloud TG, Melillo G, Scudiero DA, Cardellina JH 2nd, Shoemaker RH. Identification of a new natural camptothecin analogue in targeted screening for HIF-1alpha inhibitors. Planta Med 2007;73:49-52.
145. Clements MK, Jones CB, Cumming M, Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemotherp Pharmacol 1999;44:411-416.
146. Petrangolini G, Pratesi G, de Cesare M, Supino R, Pisano C, Marcellini M, Giordano V, Laccabue D, Lanzi C, Zunino F. Antiangiogenic effects of the novel camptothecin ST1481 (Gimatecan) in human tumor xenografts. Mol Cancer Res 2003;1:863-870.
147. Ji Y, Hayashi K, Amoh Y, Tsuji K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM. The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 2007;27:713-718.
148. Czuwara-Ladykowska J, Makiela B, Smith EA, Trojanowska M, Rudnicka L. The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis. Arthritis Res 2001;3:311-318.
149. Tudan C, Jackson J, Higo TT, Burt HM. The effect of inhibiting topoisomerase I and II on the anti-apoptotic response associated with pro-inflammatory crystals of calcium pyrophosphate dehydrate in human neutrophils. Inflamm Res 2003;52:8-17.
150. Jackson JK, Higo T, Hunter WL, Burt HM. Topoisomerase inhibitors as anti-arthritic agents. Inflamm Res 2008;57:126-134.
151. Blandizzi C, de Paolis B, Colucci R, Paolo AD, Danesi R, del Tacca M. Acetylcholinesterase blockade does not account for the adverse cardiovascular effects of the antitumor drug irinotecan: A preclinical study. Toxicol Appl Pharmacol 2001;177:149-156.
152. Bhanu MU, Kondapi AK. Neurotoxic activity of a topoisomerase-I inhibitor, camptothecin, in cultured cerebellar granule neurons. Neurotoxicology 2010;31:730-737.